CDMO Stocks: Why The Sector Could See Strong Long-Term Growth

India’s CDMO and CRDMO sector is emerging as a structural growth opportunity as global innovators increasingly work with Indian companies for drug development and commercial production. Ashish Chaturmohta, Managing Director, PMS - JM Financial, explains how India’s IP capabilities, technical expertise and cost advantages are supporting this shift. The discussion also looks at the transition from APIs and complex APIs toward peptides, hormones and GLP-1 opportunities, with some companies growing faster than the broader CDMO market. Laurus Labs, Divi’s Laboratories, Sai Life Sciences, Anthem Biosciences and Neuland Labs are highlighted as potential beneficiaries of this long-term trend, despite near-term earnings lumpiness.